Interpretation of 7-year follow-up outcomes of PERIGON trial
- VernacularTitle:PERIGON研究7年中长期随访结果解读
- Author:
Jun LI
1
;
Zheng ZUO
1
;
Chunsheng WANG
1
Author Information
1. Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai Cardiovascular Disease Institution, Shanghai, 200032, P. R. China
- Publication Type:Journal Article
- Keywords:
PERIGON trial;
bioprosthetic valve;
aortic valve disease;
surgical aortic valve replacement;
structural durability;
hemodynamic performance;
valve-related adverse events;
structural valve deterioration
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(04):652-658
- CountryChina
- Language:Chinese
-
Abstract:
With the progressive aging of the population and the evolving spectrum of aortic valve disease, bioprosthetic valve has gained widespread clinical adoption owing to their reduced requirement for lifelong anticoagulation and impact on patients’ postoperative quality of life. Consequently, the long-term durability of bioprosthetic valve has become a central focus in contemporary valvular research. The Avalus valve, representing a new generation stented bovine pericardial valve, incorporates optimized leaflet configuration, stent geometry, and anti-calcification treatment to achieve a balance between superior hemodynamic performance and structural durability. The recently reported 7-year outcomes of the PERIGON trial demonstrated excellent mid- and long-term outcomes, a remarkably low incidence of valve-related adverse events and sustained hemodynamic stability throughout follow-up. Importantly, no cases required reintervention for structural valve deterioration, underscoring the outstanding durability profile of the Avalus valve in surgical aortic valve replacement. This article reviews PERIGON trial clinical outcomes and discusses significance of the Avalus valve, as well as the future directions for bioprosthetic valve therapy in Chinese patients.
